Table 1. Engraftment capacity of MM-patient-derived BM cells vs. healthy donor and mock controls in NSG.
|
# of mice with positive Fluorescence-based in vivo imaging signal
|
Flow cytometry1
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient # | MM type | # of mice | HLA ABC | CD45 | CD138 | HLA ABC | CD45 | CD138 | CD38 |
| disease stage | with disease symptoms | d38 | d46 | d56 | d56 | d56 | d56 | d56 | |
| #1 | IgGκ MM IIIA, II SR | 4 / 4 | 4 / 4 | 4 / 4 | 4 / 4 | + | + | + | + |
| #2 | IgGλ MM IIIA, II SR | 8 / 11 | 4 / 4 | 4 / 4 | 4 / 4 | + | + | + | - |
| #3 | κ-LC MM IIIA, I HR | 1 / 1 | n.d. | n.d. | n.d. | + | n.d. | - | n.d. |
| #4 | IgGκ MM IIIA, III SR | 1 / 1 | n.d. | n.d. | n.d. | + | n.d. | - | n.d. |
| #52 | IgMκ PCL IIIA, III HR | 6 / 6 | 4 / 4 | 4 / 4 | 4 / 4 | + | + | + | - |
| #6 | IgGκ MM IIIA, II SR | 5 / 5 | 5 / 5 | 5 / 5 | 1 / 5 | - | + | + | - |
| #7 | IgAκ MM II, I HR | 5 / 5 | 5 / 5 | 5 / 5 | 0 / 5 | + | + | + | - |
| #8 | IgGκ MM III, II SR | 3 / 5 | n.d. | 3 / 3 | 2 / 3 | + | + | + | + |
| #9 | κ -LC MM IIIA, I SR | 3 / 5 | 3 / 3 | 2 / 2 | 1 / 2 | - | + | + | - |
| #10 | IgGλ MM IIIA, III SR | 3 / 5 | 5 / 5 | 5 / 5 | 3 / 5 | + | + | + | - |
| #11 | IgGκ MM IIIA, III | 10/10 | n.d. | n.d. | 10/10³ | +³ | +³ | +³ | -³ |
| Control 1 | Healthy donor | 0 / 7 | 4 / 7 | 3 / 7 | 0 / 7 | (+) | (+) | - | - |
| Control 2 | Mock-injection | 0 / 8 | 0 / 3 | 0 / 3 | 0 / 3 | - | - | - | - |
Abbreviations:
MM = Multiple Myeloma , HLA-A,B,C = human leucocyte antigen A, B and C; CD45 = Protein tyrosine phosphatase, receptor type, C; CD138 = Syndecan-1;CD38 = ADP-ribosyl cyclase;PCL = Plasma cell leukemia; n.d.= not determined
staging: Durie & Salmon and International staging systemSR=standard-risk via FISH analysis defined as no abnormalities or hyperdiploidy; HR=high-risk: +1q21, del(17p13), immunoglobulin heavy chain gene (IGH) translocation incorporating t(4;14 , t(14;16) and t(14;20).
1 Engraftment was determined via flow cytometry analysis with human engraftment defined as equal or larger as 0.08% positivity = +
BM- PB- and spleen-samples were obtained on d56, after primary intratibial injection
2 Patient 5 had a plasma cell leukemia, where peripheral blood cells were injected intratibially
3 IVI was performed weekly until day 38, flow cytometry was performed on day 38.